Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment

Benzinga_recent_news02-26

But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock. At just 10.6x ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614310650?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/25/Konskie--Poland---January-11--2024-Novo-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-26 00:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614310650","market":"us","top_or_hot":-1,"title":"Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment","media":"Benzinga_recent_news","content":"<div>\n<p>But beneath the selloff, something unusual has emerged.\nNovo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock.\nAt just 10.6x ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50857026/novo-nordisks-40-fall-may-be-creating-a-deep-value-moment\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's 40% Fall May Be Creating A Deep-Value Moment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-26 00:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/02/50857026/novo-nordisks-40-fall-may-be-creating-a-deep-value-moment><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>But beneath the selloff, something unusual has emerged.\nNovo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock.\nAt just 10.6x ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50857026/novo-nordisks-40-fall-may-be-creating-a-deep-value-moment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50857026/novo-nordisks-40-fall-may-be-creating-a-deep-value-moment","article_id":"2614310650","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/25/Konskie--Poland---January-11--2024-Novo-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50857026/novo-nordisks-40-fall-may-be-creating-a-deep-value-moment","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614310650","pubTimestamp":1772037180,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","NVOX":"2倍做多NVO ETF-Defiance","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"诺和诺德股价下跌40%可能正在创造一个深度价值时刻","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVOH":0.6,"NVO":1.96},"content_text":"But beneath the selloff, something unusual has emerged.\nNovo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock.\nAt just 10.6x earnings, NVO stock trades at a dramatic discount to both obesity-drug rival Eli Lilly and Company and broader pharma peers.\nData Source: Benzinga Pro\nThis gap is striking.\nThe market is no longer pricing Novo Nordisk as the creator of the GLP-1 obesity drug category. It's pricing it as if its leadership has already peaked.\nThe selloff reflects concerns over competition, pricing pressure, and slowing growth expectations. But valuation compression of this magnitude often signals a shift in expectations rather than a collapse in long-term relevance.\nNovo Nordisk still controls one of the most important drug platforms in modern healthcare. The global obesity drug market is expected to expand dramatically over the next decade.\nAt a 9.4% earnings yield, the stock now reflects far more pessimism than optimism.\nNovo Nordisk's collapse has erased its growth premium and replaced it with a valuation typically reserved for declining businesses.\nThat reset may prove to be the real story.\nBecause when market leaders fall this far, the opportunity often isn't in what they've lost — but in how little investors are now willing to pay for what they still control.\nPhoto: Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614310650","isCrawlerRequest":true}